anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Valsartan-Hydrochlorothiazide: No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of valsartan and hydrochlorothiazide. However, these studies have been conducted for valsartan as well as hydrochlorothiazide alone. Based on the preclinical safety and human pharmacokinetic studies, there is no indication of any adverse interaction between valsartan and hydrochlorothiazide.

Valsartan: There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at doses up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6 times, respectively, the MRHD on a mg/m2 basis (Calculations assume an oral dose of 320 mg/day and a 60-kg patient).

Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with Salmonella (Ames) and E. coli; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells; and a rat micronucleus test.

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is about 6 times the MRHD on a mg/m2 basis (Calculations assume an oral dose of 320 mg/day and a 60-kg patient).

Hydrochlorothiazide: Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.

Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of Salmonella typhimurium strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcg/mL, and in the Aspergillus Nidulans non-disjunction assay at an unspecified concentration.

Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and 1.5 times, respectively, the MRHD on a mg/m2 basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)
PCT No. PCT/FI92/00339 Sec. 371 Date Jul. 7, 1994 Sec. 102(e) Date Jul. 7, 1994 PCT Filed Dec. 10, 1992 PCT Pub. No. WO93/11757 PCT Pub. Date Jun. 24, 1993This invention relates to parenteral preparations of antiestrogens such as toremifene, desmethyl toremifene, tamoxifen or desmethyltamoxifen. The preparations can be emulsions, liposomes or aqueous solutions of cyclodextrin-drug complexes. Particularly the invention relates to a parenteral drug formulation comprising a complex having a 2-hydroxypropyl cyclodextrin component and including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present either in an aqueous solution or emulsion or loaded into a liposome.
BACKGROUND: Antibiotic treatment of unselected patients with acute appendicitis is safe and effective. However, it is unknown to what extent early provision of antibiotic treatment may represent overtreatment due to spontaneous healing of appendix inflammation. The aim of the present study was to evaluate the role of antibiotic treatment versus active in-hospital observation on spontaneous regression of acute appendicitis.
METHOD: Patients who sought acute medical care at Sahlgrenska University Hospital were block-randomized according to age (18-60 years) and systemic inflammation (C-reactive protein <60 mg/L, white blood cell <13,000/μL), in combination with clinical and abdominal characteristics of acute appendicitis. Study patients received antibiotic treatment and active observation, while control patients were allocated to classic active "wait and see observation" for either disease regression or the need for surgical exploration. According to our standard surgical care, certified surgeons in charge decided whether and when appendectomy was necessary. In total, 1,019 patients were screened for eligibility; 203 patients met inclusion criteria, 126 were accepted to participate, 29 declined, and 48 were missed for inclusion.
RESULTS: The antibiotic group (n = 69) and the control group (n = 57) were comparable at inclusion. Appendectomy at first hospital stay was 28% and 53% for study and control patients (χ2, P < .004). Life table analysis indicated a time-dependent difference in the need for appendectomy during follow-up (P < .03). Antibiotics prevented surgical exploration and appendectomy by 72% to 50% compared to 47% to 37% in the control group across the time course follow-ups between 5 and 1,200 days.
CONCLUSION: Early antibiotic treatment is superior to traditional "wait and see observation" to avoid surgical exploration and appendectomy.
Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
PURPOSE: The aim of this study was to develop a prognostic nomogram which could predict the prognosis of north Chinese patients with autoimmune cerebellar ataxia (ACA) after immunotherapy.
METHODS: Patients with an initial diagnosis of ACA who accepted first-line immunotherapy at our hospital from March 2018 to May 2023 were retrospectively reviewed. Modified Rankin Scale (mRS) was used to evaluate neurological outcomes. According to the mRS scores after immunotherapy, patients with ACA were divided into good prognosis group (mRS 0-2) and poor prognosis group (mRS 3-6). The nomogram for poor prognosis of ACA patients were built based on logistic regression analysis. The validation of the prognostic model was evaluated by concordance index (C-index), calibration curves, and decision curve analyses (DCAs).
RESULTS: A total of 86 patients with ACA who received immunotherapy at our hospital were included in this study. They were randomly divided into a training cohort (n = 60) and a validation cohort (n = 26) at a ratio of 7:3. Multivariate analyses revealed that that prognostic variables significantly related to the poor prognosis of ACA were age, elevated cerebrospinal fluid (CSF) albumin (ALB) and abnormal magnetic resonance imaging (MRI). The nomogram was constructed based on above 3 factors. The C-index of the nomogram was 0.935 (95% CI: 0.884-0.991) in the training set and 0.933 (95% CI: 0.763-0.994) in the validation set. The calibration plots for the nomogram showed that predictions of risk of poor prognosis were almost consistent with actual observations. The DCAs showed great clinical usefulness of the nomograms.
CONCLUSION: We successfully developed a nomogram to predict poor prognosis for ACA patients using risk factors of age, elevated CSF-ALB and abnormal MRI.
In activation mapping of reentrant atrial tachycardia (AT), there was no reference for window of interest (WOI). We examined the timing of a successful termination site from end of the P wave and attempted to determine whether the critical isthmus can be identified using activation mapping when WOI was set as end to end of the P wave. Forty patients with 54 reentrant AT who underwent 3D electroanatomic mapping and radiofrequency catheter ablation were evaluated retrospectively. The critical isthmus was defined as a successful termination site. We evaluate critical isthmus timing from end of the P wave and percentage of critical isthmus timing from end of the P wave to tachycardia cycle length. In 54 reentrant AT, Macro-reentry was identified in 46 (85.2%) and micro-reentry was identified in eight (14.8%). The timing of the critical isthmus site from end of the P wave was - 4.0 ± 31.1 ms (Macro-reentry vs. Micro-reentry; - 8.9 ± 29.4 ms vs. 24.0 ± 26.7 ms; P = 0.005). The percentage of critical isthmus timing from end of the P wave/tachycardia cycle length was - 1.4 ± 10.5% (Macro-reentry vs. Micro-reentry; - 3.1 ± 9.8% vs. 8.3 ± 9.3%, P = 0.004) The critical isthmus of reentrant AT is located within 10% backward and forward from end of the P wave to tachycardia cycle length. Setting the WOI from end to end of the P wave is useful for identification of the critical isthmus through activation mapping.
OBJECTIVE: The etiology of sudden sensorineural hearing loss (SSNHL) remains unknown; inflammation may be one cause. We retrospectively studied SSHNL cases in terms of the inflammatory parameters involved.
METHODS: We reviewed 169 SSNHL cases. The control group contained 132 patients with vocal cord polyps. The C-reactive protein (CRP) level, CRP/serum albumin (Alb) ratio, and neutrophil/lymphocyte ratio (NLR) were compared between the 2 groups. The relationships between these parameters and the time to treatment after SSHNL onset, hearing level, and therapeutic effects were also analyzed.
RESULTS: The CRP level, CRP/Alb ratio, and NLR were higher in SSNHL patients than in controls, but only the NLR differed significantly between the 2 groups. We found no significant differences between patients with different hearing levels, those evaluated at various times after SSNHL onset, and those with different outcomes.
CONCLUSION: The NLR is a reliable SSNHL diagnostic marker. The CRP level and CRP/Alb ratio are not useful indicators.
In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
The GCPS 2.0 is an eight-item scale that evaluates the severity of chronic pain, the presence of persistent pain due to pain days, and the degree of disability due to pain. It is easy, simple, useful and multidimensional. 80 volunteer participants who had chronic low back pain were studied.The data collection tools used in this study were; Clinic and Demographic Evaluation Form, Oswestry Low Back Pain Disability Index, Patterns of Activity Measure Pain, Roland-Morris Disability Questionnaire, Hospital Anxiety, and Depression Scale, and Graded Chronic Pain Scale 2.0. In this study, the forms were sent by e-mail. The Snowball sampling method was used in the data collection process.The stages of the Beaton Protocol were followed in the translation of the scale. Validity was evaluated with the Face, Content, and Construct validity analyses. Exploratory and confirmatory factor analyses were applied to determine the construct validity of the Turkish version of the scale. Reliability was evaluated with the test-retest method, the parallel forms method, and the internal consistency. Ten days after completing the scale, 30 participants filled out the scale again for the Test-retest method. One of the scales we used for the parallel forms method was RMDQ and the other was ODI.
FIELD: neurology. SUBSTANCE: circulating blood in amount of 8% is sampled from child. After centrifugation, 100 mg/l adenosine triphosphate and 5-10 mg Relanium are added to cellular suspension and resulting mixture is incubated for 20 min at 37 C, after which it is intravenously injected into patient in dropwise mode. Such procedure is performed 3 times at 2-day intervals. EFFECT: enhanced treatment efficiency and reduced toxic effect of Relanium. 2 tbl, 2 ex
Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned media of human melanoma cells that stimulates a myriad of biological activities including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin embedded human tissue demonstrates that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines demonstrate that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of ATX's enzymatic product, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors demonstrate structure activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against human malignancies driven by the ATX/LPA axis, especially including malignant melanoma, among numerous others including breast and ovarian cancers.
The present invention discloses a kind of method that 3D printing makes Cosmetic pack, including, the scanning of A. cosmetic facials；B. data processing；C. the preparation of Cosmetic pack material；D. the Cosmetic pack material after being sufficiently mixed is sent into 3D printer, prints the facial mask matched completely with cosmetic facial geometric properties；E. it is slight laser sintered to printed Cosmetic pack progress, form the Cosmetic pack of the network structure of nanocrystal；F. to laser sintered good Cosmetic pack, on the surface contacted with skin of face, skin care ingredient is sprayed on demand.Beneficial effect is：There is theatrical performances performing artist to be only worn over the Cosmetic pack of personalization on the face, adornment is on facial mask before performance.Meanwhile inside the facial mask contacted with skin of face, the composition of skin-care effect is may further be enriched with, while performance, carry out skin nursing.
INTRODUCTION: There is a significant demand for interventions that reduce distress related to auditory verbal hallucinations (AVHs). AVH distress is associated with the way voice hearers relate with AVHs. We aimed to establish the feasibility of a randomized controlled trial to demonstrate that adding "Relating Therapy" (RT) to treatment as usual (TAU) is superior to TAU in reducing AVH distress.
METHODS: We conducted a multicenter, parallel, single-blind, randomized controlled feasibility trial in five mental health centers in Germany. Participants were ≥19 years of age, had persistent and distressing AVHs, and had a diagnosis of a schizophrenia-spectrum disorder. RT was delivered over a maximum of 16 sessions within 5 months. Blind assessments were conducted at baseline and at 5 and 9 months. Feasibility outcomes were the number of patients recruited and retained, and safety and therapist adherence. The primary endpoint was the distress factor score of the AVH subscale of the Psychotic Symptoms Rating Scales at 9 months.
RESULTS: Eighty-five of 177 enrolled participants were randomized into RT + TAU (n = 43) or TAU (n = 42). Feasibility was excellent with 87% retention at 9 months, 86% reaching treatment uptake criteria, 98% therapist adherence, and no unexpected serious adverse reactions. Compared to TAU, RT + TAU showed nonsignificant trends toward less AVH distress (b = -2.40, SE = 1.52, p = 0.121, 90% CI (-4.94 to 0.15) and stronger improvement on all but one of the secondary outcomes.
CONCLUSION: A randomized controlled trial of RT is feasible, safe, and well accepted. Our results provide an encouraging basis to further test the efficacy of RT in a definitive multicenter trial.
PURPOSE:To provide a percutaneous absorbefacient composed of a specific phosphatidyl-choline, having excellent safety and percutaneous absorbefacient action and useful as a compounding agent for external agent for skin. CONSTITUTION:This absorbefacient is composed of a compound of the formula (R1 and R2 are each a 13-21C acyl and at least one of R1 and R2 is a group having unsaturated bond such as oleic acid residue, linoleic acid residue or linolenic acid residue), e.g. dioleylphosphatidyl-choline. The compound of formula can be produced e.g. by extracting bovine brain or chicken egg with an organic solvent such as ether, THF or chloroform and purifying by (octadecyl)silica gel column chromatography, etc. The external agent for skin to be compounded with the absorbefacient contains anti-inflammatory analgesic agent, antimycotic agent, antibacterial agent, etc., as active component and the amount of the active component and the absorbefacient is 0.01-10wt.% each based on the total amount of the external agent.
The invention relates to a pancreatic cancer drug delivery system which is composed of a multifunctional nano supporter and a basic group fragment containing a target gene. The nano supporter is composed of a dendritic high-molecular material, a hydrophilic polymer and a chelating compound including gadolinium. The nano supporter is modified by a cell penetrating peptide. The invention also relates to an application and a preparation method of the pancreatic cancer drug delivery system. In the invention, locally high-efficient delivery of the drug delivery system is achieved through a mechanism that the cell penetrating peptide can penetrate a tumor matrix and a cancer cell membrane of pancreatic cancer in a high performance and high-efficient gene transfection in pancreatic cancer cells by means of characteristics that interventional therapy is visible, is less in wounding, is high in locally drug delivery efficiency and is less in wounding on normal organs. An experimental result proves that the pancreatic cancer drug delivery system has an excellent treatment effect. The pancreatic cancer drug delivery system is easy to prepare, is high in stability, is free of immunogenicity and is good in clinical application prospect.
BACKGROUND: Computerised static visual field testing using dedicated machines such as the Humphrey Field Analyzer (HFA) can assess and track changes in visual field sensitivity. The use of retrospective visual field databases is a novel undertaking, with no studies published utilising large scale population-level data. This study phase developed a method to extract HFA data into a large standardised population-based database including point sensitivity data with additional derived variables.
METHODS: Retrospective, longitudinal, population study of visual field data from people who attended an ophthalmology service and had a HFA field test, in Western Australia, between 1988 and 2022. Raw test data included patient demographic fields, sensitivity readings and test parameters. Calculated fields included reliability scores, and a novel combined reliability score.
RESULTS: There were 606 230 tests for 92 215 study individuals, from 22 ophthalmology practices in metropolitan Perth and three public hospital eye clinics, representing around 85% of the field tests performed by ophthalmologists each year. Raw sensitivity values were available for all tests, and additional descriptors were available for most tests (97.5%-100% of tests) with the exception of data variables retired by the manufacturer.
CONCLUSIONS: Visual field data from 606 230 tests were collated into a single dataset, which is highly representative over a long period of time, for a defined population. This dataset has been linked to other administrative datasets to allow for epidemiological investigation of field of vision disorders.
Peptides or a mixture of peptides derived from the variable domains of the Chlamydia trachomatis (C. trachomatis) immunodominant major outer membrane protein (MOMP), said peptides or mixtures of peptides characterized by having specificity only to C. trachomatis anti-MOMP antibodies and being non-cross reactive with anti-MOMP antibodies of other Chlamydia species, said peptides selected from: (a) SEQ ID NO. 1, herein also designated peptide 4A, having the amino acid sequence: I F D T T L N P T I A G A G D V K; (b) SEQ ID NO. 2, herein also designated peptide 4B having the amino acid sequence: V D I T T L N P T I A G C G S V A K; (c) SEQ. ID NO. 3, herein also designated peptide 4C, having the amino acid sequence: C V F D V T T L N P T I A G A G D V K; (d) SEQ. ID NO. 4, herein also designated peptide 4D, having the amino acid sequence: L A E A I L D V T T L N P T I T G K A V V S K; wherein all of said peptides (a)-(d) are derived from the fourth variable domain (VDIV) of said MOMP; (e) SEQ. ID NO. 5, herein also designated peptide C.t2A, having the amino acid sequence: C D N E N Q S T V K T N S V P N M S L D Q S K, wherein said peptide (e) is derived from the second variable domain (VDII) of said MOMP; (f) SEQ. ID NO. 6, herein also designated as C.t VDI, having the amino acid sequence: V A G L E N D P T T N V A R A; (g) SEQ. ID NO. 7, herein also designated as C.t VDII, having the amino acid sequence: D N E N N A T V S D S K L V P N H M S D Q S; (h) SEQ. ID NO. 8, herein also designated as C.t VDIV, having the amino acid sequence: L D V T T N A T I A G K G T V V; (i) analogs of any one of peptides (a)-(h), wherein said analogs have essentially the same biological activity as said peptides (a)-(h), said analogs having between about 9 to about 35 amino acid residues and differing from said peptides (a)-(h) by having one or more additions, deletions or substitutions, or by being combinations of an N-terminal part of one peptide selected from (a) to (d) or (h) with a C-terminal part of another peptide selected from (a) to (d) or (h), such that that the complete sequence will be homologous to the VDIV sequence, or by being combinations of an N-terminal part of one peptide selected from (e) or (g) with a C-terminal part of another peptide selected from (e) or (g), such that the complete sequence will be homologous to the VDII sequence.
273,349. Dehn, F. B., (Lilly & Co., E.). Jan. 4, 1926. Antitoxins, toxins, vaccines, and immunizing and like serums; bacteria, cultivating.-Bacteria or their products or toxins, or both, are attenuated or detoxified by treatment in vitro with a surface tension depressant consisting of a soluble salt of an organic acid. According to examples, a whole culture of streptococci or staphylococci, living or dead, or a toxin such as diphtheria or scarlet fever toxin, is treated with sufficient of a 20 per cent solution of sodium ricinoleate to give a final concentration of 2 per cent. The products may be used for direct treatment of human beings or animals, or may be injected into animals from which the corresponding anti-toxic serum is then obtained. The surface tension depressant is stated to be adsorbed on the bacteria or toxin molecules. Large doses of the products may be injected. Other bacteria and toxins specified are pneumococci and scarlet fever streptococci and their toxins, also tetanus toxin : other surface tension depressants are soluble salts of higher fatty acids, and sodium proteinates such as gelatinate or caseinate. The prior use of bile and bile salts to enrich bacteria culture media, and, in high concentrations, to cause bacteriolysis of pneumococci, is referred to.